Piper Sandler lowered the firm’s price target on NeoGenomics (NEO) to $18 from $21 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics: Strong Core Business and Growth Catalysts Justify Buy Rating Despite Challenges
- NeoGenomics price target lowered to $17 from $18 at BTIG
- NeoGenomics price target lowered to $19 from $20 at TD Cowen
- NeoGenomics price target lowered to $16 from $19 at BofA
- NeoGenomics Achieves Double-Digit Revenue Growth in 2024